肿瘤BRCA1/2突变在局限或转移性激素敏感性前列腺癌中的患病率与临床影响
这项多中心国际回顾性队列研究纳入2013—2019年接受肿瘤BRCA1和BRCA2测序的局限性和新发转移性激素敏感性前列腺癌患者,评估肿瘤BRCA突变(tBRCAm)的患病率与临床结局。结果显示,tBRCAm在局限性疾病中似与更高的复发风险相关,但未影响接受常规治疗的新发转移性激素敏感性前列腺癌患者的临床结局,提示tBRCAm在不同临床阶段可能具有不同的预后作用。
要点
- 局限性HSPC中tBRCAm患病率为3.1%(8/258),新发转移性HSPC为10.6%(15/141)。
- 局限性队列中tBRCAm者的EFS为18.1个月对57个月(p=0.28),MFS为37个月对153.4个月(p=0.08)。
- 转移性队列中tBRCAm者的TTCRPC为24个月对19个月(p=0.65),OS为64个月对60个月(p=0.95)。
核心结论
- tBRCAm在局限性疾病中似与更高的复发风险相关,但未影响接受常规治疗的新发转移性HSPC患者的临床结局。
- tBRCAm可能在前列腺癌不同临床阶段中发挥不同的预后作用。
研究设计与样本
- 多中心、国际、回顾性队列研究,纳入2013—2019年接受肿瘤BRCA1和BRCA2测序的HSPC患者。
- 队列1为局限性HSPC,队列2为新发转移性HSPC,共399例患者。
- 队列1的258例中8例(3.1%)携带tBRCAm,队列2的141例中15例(10.6%)携带tBRCAm。
- 队列1主要终点为无事件生存期(EFS)和无转移生存期(MFS),队列2为至去势抵抗性前列腺癌时间(TTCRPC)和总生存期(OS)。
- 采用Kaplan-Meier法和Cox回归模型评估终点与tBRCA状态的关联。
主要发现
- 队列1中位随访33个月,队列2中位随访36个月。
- 队列1中tBRCAm者与无tBRCAm者的中位EFS为18.1个月对57个月(p=0.28),中位MFS为37个月对153.4个月(p=0.08)。
- 队列2中tBRCAm者与无tBRCAm者的TTCRPC为24个月对19个月(p=0.65),OS为64个月对60个月(p=0.95)。
临床怎么用
- 对局限性或新发转移性HSPC患者可考虑肿瘤BRCA1和BRCA2测序以了解tBRCA状态。
- 携带tBRCAm的局限性疾病患者或需关注更高的复发风险,但tBRCAm状态不应单独改变新发转移性HSPC的常规治疗预期。
局限性
- 研究为回顾性设计。
- tBRCAm亚组样本量小(队列1为8例,队列2为15例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The appropriate management of localized or metastatic hormone-sensitive prostate cancer (HSPC) patients harboring tumor BRCA mutations (tBRCAm) is not well-characterized. We sought to evaluate the prevalence and clinical outcomes of patients with tBRCAm and localized or de novo metastatic HSPC. METHODS: We performed a multicenter, international, retrospective cohort study of localized (cohort 1) and de novo metastatic (cohort 2) HSPC patients who underwent tumor BRCA1 and BRCA2 sequencing from 2013 to 2019. Primary endpoints included event-free survival (EFS) and metastases-free survival (MFS) for cohort 1, and time to castration-resistant prostate cancer (TTCRPC) and overall survival (OS) for cohort 2. Kaplan-Meier method and Cox regression models estimated the association of endpoints with tBRCA status. RESULTS: Of 399 identified patients with localized and de novo metastatic HSPC who underwent tumor BRCA1 and BRCA2 sequencing, 3.1% (8/258) patients of cohort 1 and 10.6% (15/141) patients of cohort 2 harbored tBRCAm. The median follow-up was 33 and 36 months, respectively. In cohort 1, median EFS was 18.1 vs. 57 months (p = 0.28) and MFS was 37 vs. 153.4 months (p = 0.08) for patients with tBRCAm compared to patients with no tBRCAm. In cohort 2, the TTCRPC was 24 vs. 19 months (p = 0.65) and OS was 64 vs. 60 months (p = 0.95) in patients with and without tBRCAm, respectively. CONCLUSIONS: While tBRCAm seems to be associated with greater relapse risk in localized disease, tBRCAm did not influence the clinical outcomes of patients presenting with de novo metastatic HSPC treated with conventional therapies. tBRCAm may exert different prognostic effects across the clinical spectrum of prostate cancer.
引用
- Martinez Chanza N, Bernard B, Barthelemy P, et al. Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 34108647. doi:10.1038/s41391-021-00397-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。